What researchers have shown, and what they are testing now.

Guidelines and consensus

No AHA, ACC or ESC POTS guideline existed when we checked. These are the documents clinicians use.

• Heart Rhythm Society expert consensus, 2015

  Defines POTS, rates treatments by class and level, and says to try non-drug treatment first. Still the most cited US statement.

• Canadian Cardiovascular Society position statement, 2020

  GRADE-based review that warns many people labeled POTS do not meet criteria.

• NIH expert consensus meeting, Part 1 (2021)

  State of the science from a 2019 meeting: criteria, mechanisms and the list of conditions to exclude.

• CMAJ clinical review, 2022

  A practical diagnosis and management review for clinicians, with the core lab workup.

• JAMA review, 2026

  The most recent major review: criteria, epidemiology and first-line care.

• International Delphi consensus, American Journal of Medicine, 2026

  Forty experts reach more than 90% agreement on 31 statements and argue that many patients under the 30 or 40 bpm line still need care. Consensus paper, not a formal guideline.

Long COVID and POTS

• Bjornson 2025, Circulation: Arrhythmia and Electrophysiology

  31% of 467 highly symptomatic long COVID patients met POTS criteria about a year after infection.

• Wang 2025, Frontiers in Cardiovascular Medicine

  Meta-analysis of 21 studies pooled POTS at 36% of tested post-COVID patients, with signs of publication bias.

• Dulal 2025, European Heart Journal: Quality of Care and Clinical Outcomes

  New POTS diagnoses rose from 1.42 to 20.3 per million person-years after the pandemic began.

Treatment trials

• Garland 2021, JACC: dietary sodium

  A high-sodium diet lowered the heart rate rise and raised plasma volume in 14 patients over 6 days.

• Bourne 2021, JACC: compression garments

  Heart rate on tilt fell from 109 to 92 bpm as garment coverage grew, in 30 adults.

• Taub 2021, JACC: ivabradine

  The only randomized trial of ivabradine in POTS, 22 patients with the hyperadrenergic type.

• Vernino 2024, iSTAND: IV immunoglobulin

  No difference from albumin in 30 treated patients with presumed autoimmune POTS.

• Kwok 2025, Trends in Cardiovascular Medicine

  Systematic review of 21 randomized trials (750 patients) concludes large trials are needed.

Causes and associations

• Hall 2022, Circulation: autoantibodies

  A study of 116 patients and 81 controls found no difference in adrenergic receptor antibodies using standard methods.

• Farley 2025, Annals of Allergy, Asthma and Immunology

  A systematic review found no study that met its criteria to confirm a mast cell link.

• Miller 2020, Autonomic Neuroscience: hypermobility

  31% of 91 POTS patients met criteria for hypermobile Ehlers-Danlos syndrome.

Outcomes and measurement

• Boris 2024, Journal of the American Heart Association

  In 227 people with childhood-onset POTS, 99% still reported symptoms at about 10 years.

• Stewart and Medow 2025, Clinical Autonomic Research

  In young people, a 5-minute stand was less accurate than a 10-minute tilt for diagnosing POTS.

• Choe and Kang 2025, Physiological Measurement

  Apple Watch heart rate had limits of agreement near 11 bpm versus reference devices in a 56-study meta-analysis.

Trials to watch

Statuses come from the registry records and can change. Search more at ClinicalTrials.gov.

• NCT05924646: Calgary salt study

  Recruiting. Tests salt as treatment, estimated completion 2028.

• NCT04186286: propranolol versus ivabradine

  Randomized crossover in Calgary, listed as recruiting.

• NCT07189936: 2-HOBA in long COVID POTS

  Phase 2 at Vanderbilt, recruiting since December 2025.

• RECOVER-AUTONOMIC (NCT06305780)

  Platform trial of IVIG and ivabradine in long COVID POTS. Registered as completed. We found no published results yet.

• NCT06593600: REGN7544

  Phase 2 single-dose study by Regeneron. Listed as completed with no results posted.